Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Phase II Clinical Study of Adjuvant Apatinib After IMRT With Concurrent Chemotherapy Versus IMRT With Concurrent Chemotherapy in High-risk Metastasis of Nasopharyngeal Carcinoma

NCT03612219 is registered in ClinicalTrials.gov with Wei Jiang as lead sponsor.

NCT NCT03612219
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03612219 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Phase II Clinical Study of Adjuvant Apatinib After IMRT With Concurrent Chemotherapy Versus IMRT With Concurrent Chemotherapy in High-risk Metastasis of Nasopharyngeal Carcinoma
Lead sponsor
Wei Jiang
Phase
Phase 2
Overall status
Unknown status
Start date
July 1, 2018
Completion date
July 28, 2021
Enrollment
240 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

nasopharyngeal carcinoma